$UNH (+1,32 %)
$NOVO B (+1,22 %)
$HIMS (+2,03 %)
$LLY (+0,96 %)
$M2PW34
$BNTX (+2,35 %)
$OSCR

BioNTech SE ADR
Price
Debate sobre BNTX
Puestos
231Dates week 25
As every Sunday, the most important news from the past week, as well as the most important dates for the coming week.
Also as a video:
https://youtube.com/shorts/Qnq0Hgw02ok?si=c1DdZaCBPcjb9KK5
Monday:
The Japanese economy contracted slightly less than feared in the first quarter. However, there is still a risk of recession. The annualized figure was only 0.2 % instead of 0.7 %.
Wednesday:
The tariffs have hardly had any impact on US inflation so far, but the inflation rate has nevertheless risen to 2.4%. Both core inflation and actual inflation were 10 basis points below expectations, with housing costs being the strongest driver of inflation.
Thursday:
Tragic accident in India with a $BA (-0,92 %) Boeing aircraft. Unfortunately, accidents involving Boeing aircraft occur at regular intervals. The cause of the crash remains unclear for the time being.
The Mainz-based biotech company $BNTX (+2,35 %) Biontech looks set to buy Tübingen-based competitor $CVAC (-0,43 %) Curevac. Curevac is valued at around 1 billion euros. The German government is thus making a loss of around 130 million euros on its investment in Curevac, proving once again why the state is not a good investor.
Friday:
Isreal's attack on Iran had been looming since yesterday. Negotiations with the USA on ending the nuclear weapons program stalled. Trump had embassy staff in Iraq withdrawn yesterday.
https://m.bild.de/politik/israel-greift-iran-an-explosionen-im-raum-teheran-684b71ab8858611e27641106
These are the most important dates for the coming week:
Wednesday: 20:00 Interest rate decision (USA)
Thursday: 13:00 Interest rate decision (UK)
Friday: 01:30 BoJ meeting minutes (Japan)
SAP under antitrust investigation | Biontech acquires Curevac in billion-euro deal
SAP $SAP (+1,83 %) is being targeted by the German Federal Cartel Office, which has recently launched an investigation into the acquisition of Signavio. This measure is a reaction to the accusations made by competitor Celonis, which accuses SAP of alleged misconduct. In 2021, the software giant acquired Signavio for almost one billion euros, which was approved by the regulatory authorities at the time. Signavio was a direct competitor of Celonis, and the ongoing investigations could have a lasting impact not only on the acquisition but also on SAP's entire market position. The industry is watching with interest to see how the situation will develop and what consequences this could have for SAP.
In another major move, Biontech $BNTX (+2,35 %) announced the acquisition of Curevac $CVAC (-0,43 %) which is seen as a significant step forward for the company. According to a pharmaceutical executive close to owners Thomas and Andreas Strüngmann, this deal reflects the strength of Biontech. At the important conference of the American Society of Clinical Oncology (ASCO) at the end of May, Biontech presented promising results that further fueled interest in the company. As part of the takeover, Curevac shares are to be exchanged for Biontech depositary receipts, which catapulted the Curevac share price up to 28 percent. As a result, the market capitalization returned to the level of the beginning of the year. Nevertheless, the valuation of Curevac shares remains 95% below the 2020 records, which shows how volatile the market for biopharmaceutical companies is.
Sources:
Crazy deal
$BNTX (+2,35 %) The companies will work together to develop and eventually sell BNT327, one of BioNTech's developmental antibodies that is in trials to treat a number of types of tumors. More than 20 trials are ongoing or planned to study the drug's effectiveness in treating certain lung, breast, and other types of cancer.
Princeton, N.J.-based Bristol Myers Squibb "will pay BioNTech $1.5 billion in an upfront payment and $2 billion total in non-contingent anniversary payments through 2028." BioNTech is also eligible to receive up to $7.6 billion in future payments based on certain developmental and regulatory milestones, while the companies will share manufacturing costs and profits or losses.
Meine mit ein Medikament das Potenzial der ganzen Market cap raus zuholen ist schon crazy. Mal schauen wie die ganze Pipeline aussieht
Derivatives Trading Part 2
Good evening everyone, as I won't be here much tomorrow, I've decided to send you the second part today. I'm devoting myself to one of my favorite, but generally not very widespread species of derivatives, namely the Inline OS. There is no long or short here, as they are suitable for sideways phases.
With inline OSs such as the one shown here, there is a range within which the underlying must move over the entire term. If the upper or lower limit is breached, the bond expires worthless. However, if it remains within the range for the entire term, the bill is always redeemed at € 10 at the end. The bill below is based on the €/SFR rate (0.92/0.97) and runs until June 5, i.e. 2 weeks. I bought it at €1.90 when it was quite close to the lower limit. I mostly trade currency pairs or oil with these bills. Stocks also work, but I would only take large stocks. At the moment I have one on $BNTX (+2,35 %) and on $RHM (-2,21 %) . Smaller, more market-oriented stocks can easily be pushed over the barrier by the issuer if they are close to one of the limits. That's why I stay away from them.
So the topic is relatively easy to deal with. Nevertheless, I hope it has been informative for you. If you have any questions about this very interesting product, please feel free to ask.
I wish you all a pleasant evening.
But which platform do you use to find such certificates and options etc? I currently use onvista, Börse.de and Wallstreet online (I don't like them 100%
What's wrong with
$BNTX (+2,35 %) go. -20% is a lot in 2 hours. Have research results been leaked?
Summit Therapeutics' shares plummeted on Friday. The reason for this was a report by the specialist portal Stat News, according to which the survival data from an ongoing study on the experimental lung cancer drug Ivonescimab failed to meet expectations. BioNTech shares also crashed, as the Mainz-based company is working on a similar cancer immunotherapy.
Specifically, it concerns an interim analysis of the study: after the death of 157 patients, it was shown that Ivonescimab only reduced the risk of death by around 22 percent - with a hazard ratio of 0.784. The hazard ratio is a statistical parameter that indicates how much a drug reduces the risk of a certain event - in this case death - compared to the control group.
A value of 1.0 means: no difference between the groups.
A value of less than 1.0 indicates: the risk is lower with treatment.
The closer to 0, the better the effectiveness.
The cancer drug has therefore not had the desired impact and has also fallen well short of analysts' expectations: Truist expert Asthika Goonewardene had set a ratio of less than 0.7 in his baseline estimate at the beginning of April. A ratio of 0.8 was considered his worst-case scenario.
Summit Therapeutics shares plummeted by almost 40 percent on Friday and were even suspended from trading. BioNTech shares were also hit hard, falling by more than 20 percent. The reason: BioNTech's active ingredient Gotistobart is comparable to Ivonescimab, threatening similarly poor results.
Subsequent purchase - BioNTech
Today again something at $BNTX (+2,35 %) today. The position will soon be full and my savings plan stopped.
BionTech sell-off triggered by resignation / dismissal of Dr. Peter Marks
$BNTX (+2,35 %) has taken quite a beating in pre-market trading today. R.F. Kennedy and Peter Marks (FDA) have parted ways following differences of opinion on the subject of vaccinations. The vaccine values such as $BNTX (+2,35 %) and $MRNA (+4,5 %) have suffered. For me, this is a good opportunity to add to my BionTech position right after the US IPO - I am speculating on a breakthrough in the oncology pipeline in 2026. Biontech is one of my long term swings.
In addition to Biontech, I also added to my $RDC (+5,67 %) Shopapotheke position again today.
Valores en tendencia
Principales creadores de la semana